scholarly journals Collaborative research in Australasian plastic surgery

2021 ◽  
Vol 4 (2) ◽  
pp. 5-7
Author(s):  
Guy HM Stanley ◽  
Melissa J Hirth ◽  
Michael W Findlay

Many specialist groups have developed clinical trial initiatives in response to the growing need for more collaborative research, and these are proliferating in multiple countries across the globe. The Royal Australasian College of Surgeons (RACS), under the direction of Professor John Windsor, established the clinical trials network of Australia and New Zealand (CTANZ). CTANZ supports the Australasian clinical trials in plastic, reconstructive and aesthetic surgery (ACTPRAS) research group which has already facilitated two multicentre, international, collaborative studies.

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Laura Robison ◽  
◽  
Yeoungjee Cho ◽  
Andrea K. Viecelli ◽  
David W. Johnson ◽  
...  

AbstractThe unprecedented demand placed on healthcare systems from the COVID-19 pandemic has forced a reassessment of clinical trial conduct and feasibility. Consequently, the Australasian Kidney Trials Network (AKTN), an established collaborative research group known for conducting investigator-initiated global clinical trials, had to efficiently respond and adapt to the changing landscape during COVID-19. Key priorities included ensuring patient and staff safety, trial integrity and network sustainability for the kidney care community. New resources have been developed to enable a structured review and contingency plan of trial activities during the pandemic and beyond.


2018 ◽  
Vol 1 (1) ◽  
pp. 132-136
Author(s):  
Olivia M Perotti ◽  
Storm Holwill ◽  
Sadhishaan Sreedharan ◽  
Daniel J Reilly ◽  
Warren M Rozen ◽  
...  

Background: Bibliometrics is the analysis of research produced by individuals and institutions. While previous analyses have assessed sub-specialty fields, as well as contributions of individual countries to the plastic surgical literature, no bibliometric analyses to date have measured the contribution of plastic surgeons from Australia and New Zealand.Methods: Plastic surgery journals with the 15 highest impact factors were identified. Total publications in a ten-year period from October 2007 to September 2017 by Australian and New Zealand Plastic Surgeons were recorded, as were h-indices for all surgeons.Results: 588 articles were published by 498 surgeons, with the largest numbers in Plastic and Reconstructive Surgery (142), Burns (133), and the Journal of Plastic, Reconstructive and Aesthetic Surgery (112). Mean h-index for Associate Professors was 9.29, and for Professors was 17.17.Conclusion: Australian and New Zealand plastic surgeons continue to be actively involved in world-class research and innovation. The volume and quantity of research produced supports the development of an Australasian Journal of Plastic Surgery.


2009 ◽  
Vol 13 (05) ◽  
pp. 35-53

Alchemia Collaborates on SK1. Progen Technology Switches On Cancer Fighting Genes. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers. Novavax and Cadila Pharmaceuticals Form Alliance. Icon's Singapore, India Labs Get CAP Accreditation. SIRO Clinpharm and Advanced Clinical Trial Solutions Form Strategic Alliance. GVK Forays into Clinical Trials with Chinese Company. iZumi Bio and Kyoto University Collaborate on iPS Cell Technology. Vitrolife Starts a Company in Japan. Otsuka, BMS in an Oncology Collaboration. EnVivo, Mitsubishi to Develop Schizophrenia Drug. PerkinElmer Announces Collaboration with Sangmyung University. Living Cell Technologies's New Zealand Pigs Free of Viruses. A*STAR Joins Forces with Swiss Company, Cytos, to Combat HFMD. IBN Engineers World's First Tri-Continuous Mesoporous Silica. Innogene Kalbiotech Pte Ltd and Info Kinetics Sdn. Bhd. Spearhead Establishment of Internationally Accredited BA/BE Studies in Indonesia.


BMJ Open ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. e019983 ◽  
Author(s):  
Kylie Elizabeth Hunter ◽  
Anna Lene Seidler ◽  
Lisa M Askie

ObjectivesTo analyse prospective versus retrospective trial registration trends on the Australian New Zealand Clinical Trials Registry (ANZCTR) and to evaluate the reasons for non-compliance with prospective registration.DesignPart 1: Descriptive analysis of trial registration trends from 2006 to 2015. Part 2: Online registrant survey.ParticipantsPart 1: All interventional trials registered on ANZCTR from 2006 to 2015. Part 2: Random sample of those who had retrospectively registered a trial on ANZCTR between 2010 and 2015.Main outcome measuresPart 1: Proportion of prospective versus retrospective clinical trial registrations (ie, registration before versus after enrolment of the first participant) on the ANZCTR overall and by various key metrics, such as sponsor, funder, recruitment country and sample size. Part 2: Reasons for non-compliance with prospective registration and perceived usefulness of various proposed mechanisms to improve prospective registration compliance.ResultsPart 1: Analysis of the complete dataset of 9450 trials revealed that compliance with prospective registration increased from 48% (216 out of 446 trials) in 2006 to 63% (723/1148) in 2012 and has since plateaued at around 64%. Patterns of compliance were relatively consistent across sponsor and funder types (industry vs non-industry), type of intervention (drug vs non-drug) and size of trial (n<100, 100–500, >500). However, primary sponsors from Australia/New Zealand were almost twice as likely to register prospectively (62%; 4613/7452) compared with sponsors from other countries with a WHO Network Registry (35%; 377/1084) or sponsors from countries without a WHO Registry (29%; 230/781). Part 2: The majority (56%; 84/149) of survey respondents cited lack of awareness as a reason for not registering their study prospectively. Seventy-four per cent (111/149) stated that linking registration to ethics approval would facilitate prospective registration.ConclusionsDespite some progress, compliance with prospective registration remains suboptimal. Linking registration to ethics approval was the favoured strategy among those sampled for improving compliance.


2018 ◽  
Vol 1 (1) ◽  
pp. 130-134
Author(s):  
Olivia M Perotti ◽  
Storm Holwill ◽  
Sadhishaan Sreedharan ◽  
Daniel J Reilly ◽  
Warren M Rozen ◽  
...  

Background: Bibliometrics is the analysis of research produced by individuals and institutions. While previous analyses have assessed sub-specialty fields, as well as contributions of individual countries to the plastic surgical literature, no bibliometric analyses to date have measured the contribution of plastic surgeons from Australia and New Zealand.Methods: Plastic surgery journals with the 15 highest impact factors were identified. Total publications in a ten-year period from October 2007 to September 2017 by Australian and New Zealand Plastic Surgeons were recorded, as were h-indices for all surgeons.Results: 588 articles were published by 498 surgeons, with the largest numbers in Plastic and Reconstructive Surgery (142), Burns (133), and the Journal of Plastic, Reconstructive and Aesthetic Surgery (112). Mean h-index for Associate Professors was 9.29, and for Professors was 17.17.Conclusion: Australian and New Zealand plastic surgeons continue to be actively involved in world-class research and innovation. The volume and quantity of research produced supports the development of an Australasian Journal of Plastic Surgery.


1990 ◽  
Vol 29 (03) ◽  
pp. 243-246 ◽  
Author(s):  
M. A. A. Moussa

AbstractVarious approaches are considered for adjustment of clinical trial size for patient noncompliance. Such approaches either model the effect of noncompliance through comparison of two survival distributions or two simple proportions. Models that allow for variation of noncompliance and event rates between time intervals are also considered. The approach that models the noncompliance adjustment on the basis of survival functions is conservative and hence requires larger sample size. The model to be selected for noncompliance adjustment depends upon available estimates of noncompliance and event rate patterns.


Author(s):  
Subha Sankar Paul ◽  
Goutam Biswas

: COVID-19 is a public health emergency of international concern. Although, considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2, till date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir which have shown promising results in different advanced stage of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir-Ritonavir combination, although initially was hypothesized to be effective against SARS-CoV-2, are now discontinued from the solidarity clinical trials. This review provides a brief description of their chemical syntheses along with their mode of action and clinical trial results available in Google and different peer reviewed journals till 24th October 2020.


2019 ◽  
Vol 14 (3) ◽  
pp. 160-172 ◽  
Author(s):  
Aynaz Nourani ◽  
Haleh Ayatollahi ◽  
Masoud Solaymani Dodaran

Background:Data management is an important, complex and multidimensional process in clinical trials. The execution of this process is very difficult and expensive without the use of information technology. A clinical data management system is software that is vastly used for managing the data generated in clinical trials. The objective of this study was to review the technical features of clinical trial data management systems.Methods:Related articles were identified by searching databases, such as Web of Science, Scopus, Science Direct, ProQuest, Ovid and PubMed. All of the research papers related to clinical data management systems which were published between 2007 and 2017 (n=19) were included in the study.Results:Most of the clinical data management systems were web-based systems developed based on the needs of a specific clinical trial in the shortest possible time. The SQL Server and MySQL databases were used in the development of the systems. These systems did not fully support the process of clinical data management. In addition, most of the systems lacked flexibility and extensibility for system development.Conclusion:It seems that most of the systems used in the research centers were weak in terms of supporting the process of data management and managing clinical trial's workflow. Therefore, more attention should be paid to design a more complete, usable, and high quality data management system for clinical trials. More studies are suggested to identify the features of the successful systems used in clinical trials.


2019 ◽  
Author(s):  
Allison Hirsch ◽  
Mahip Grewal ◽  
Anthony James Martorell ◽  
Brian Michael Iacoviello

BACKGROUND Digital Therapeutics (DTx) provide evidence based therapeutic health interventions that have been clinically validated to deliver therapeutic outcomes, such that the software is the treatment. Digital methodologies are increasingly adopted to conduct clinical trials due to advantages they provide including increases in efficiency and decreases in trial costs. Digital therapeutics are digital by design and can leverage the potential of digital and remote clinical trial methods. OBJECTIVE The principal purpose of this scoping review is to review the literature to determine whether digital technologies are being used in DTx clinical research, which type are being used and whether publications are noting any advantages to their use. As DTx development is an emerging field there are likely gaps in the knowledge base regarding DTx and clinical trials, and the purpose of this review is to illuminate those gaps. A secondary purpose is to consider questions which emerged during the review process including whether fully remote digital clinical research is appropriate for all health conditions and whether digital clinical trial methods are inline with the principles of Good Clinical Practice. METHODS 1,326 records were identified by searching research databases and 1,227 reviewed at the full-article level in order to determine if they were appropriate for inclusion. Confirmation of clinical trial status, use of digital clinical research methods and digital therapeutic status as well as inclusion and exclusion criteria were applied in order to determine relevant articles. Digital methods employed in DTx research were extracted from each article and these data were synthesized in order to determine which digital methods are currently used in clinical trial research. RESULTS After applying our criteria for scoping review inclusion, 11 articles were identified. All articles used at least one form of digital clinical research methodology enabling an element of remote research. The most commonly used digital methods are those related to recruitment, enrollment and the assessment of outcomes. A small number of articles reported using other methods such as online compensation (n = 3), or digital reminders for participants (n = 5). The majority of digital therapeutics clinical research using digital methods is conducted in the United States and increasing number of articles using digital methods are published each year. CONCLUSIONS Digital methods are used in clinical trial research evaluating DTx, though not frequently as evidenced by the low proportion of articles included in this review. Fully remote clinical trial research is not yet the standard, more frequently authors are using partially remote methods. Additionally, there is tremendous variability in the level of detail describing digital methods within the literature. As digital technologies continue to advance and the clinical research DTx literature matures, digital methods which facilitate remote research may be used more frequently.


Sign in / Sign up

Export Citation Format

Share Document